OpenAI just made a bold move into biotech — acquiring startup Orchestra Bio to accelerate its life sciences AI ambitions. The team and technology will power Rosalind, OpenAI's AI model built specifically for biological research, along with the Rosalind Workbench — a tool designed to help scientists plan experiments and interpret results more efficiently. This isn't just another tech acquisition. It signals that AI giants are increasingly targeting drug discovery, genomics, and lab automation as the next frontier. As AI becomes the new microscope, the race to own life sciences infrastructure is heating up fast. The convergence of machine learning and molecular biology could redefine how we develop medicines and understand disease. Companies in this space: OpenAI (private), Alphabet/Google DeepMind ($GOOGL, NASDAQ), Recursion Pharmaceuticals ($RXRX, NASDAQ), Nvidia ($NVDA, NASDAQ)